Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139044 | 0.98 | CES2 (0.59) | CES2CES1LMNANPC1RAB9A | |
| Acetic Acid SCHEMBL3368380 | 0.95 | CES2 (0.56) | CES2CES1LMNANPC1RAB9A | |
| SCHEMBL28343389 | 0.94 | CES2 (0.54) | CES2CES1LMNANPC1RAB9A | |
| Carbamic Acid SCHEMBL1695357 | 0.94 | CES2 (0.54) | CES2CES1LMNANPC1RAB9A | |
| Phosphoric Acid SCHEMBL9151566 | 0.92 | CES2 (0.53) | CES2CES1LMNANPC1RAB9A | |
| Acrylic Acid SCHEMBL10353178 | 0.90 | CES2 (0.50) | CES2CES1LMNANPC1RAB9A | |
| SCHEMBL3364576 | 0.87 | CES2 (0.47) | CES2CES1LMNANPC1RAB9A | |
| Bicarbonate SCHEMBL2779583 | 0.87 | LMNA (0.58) | CES2CES1LMNANPC1RAB9A | |
| SCHEMBL8622126 | 0.86 | CES2 (0.61) | CES2CES1LMNANPC1RAB9A | |
| SCHEMBL139043 | 0.85 | LMNA (0.59) | CES2CES1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-118139851-A | Antitumor compounds | 法马马有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| US-20080199874-A1 | CONTROLLABLE STRAND SCISSION OF MINI CIRCLE DNA | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080176769-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153100-A1 | substrates having selected active chemical regions by employing elements of the substrates in assisting the localization of active chemical groups in desired regions of the substrate. The methods may include optical, chemical and/or mechanical processes for deposits | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080050747-A1 | Articles having localized molecules disposed thereon and methods of producing and using same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080032301-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080009007-A1 | CONTROLLED INITIATION OF PRIMER EXTENSION | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007123763-A2 | ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070238679-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | CES2 2944/4885CES1 1024/4885LMNA 1898/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | CES2 2686/4885CES1 2760/4885LMNA 1550/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | CES2 2410/4885CES1 1910/4885LMNA 1254/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | CES2 2944/4885CES1 1024/4885LMNA 1898/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | CES2 3538/4885CES1 3251/4885LMNA 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.